Comparison of Sirolimus- vs Paclitaxel-Coated Balloon Angioplasty for Femoropopliteal Artery Disease: The SIRONA Randomized Noninferiority Trial - PubMed
2 days ago
- #sirolimus
- #angioplasty
- #peripheral artery disease
- Comparison of Sirolimus- vs Paclitaxel-Coated Balloon Angioplasty for Femoropopliteal Artery Disease in the SIRONA trial.
- Paclitaxel-coated balloon (PCB) angioplasty is effective but associated with increased mortality risk.
- Sirolimus-coated balloon (SCB) angioplasty was tested for noninferiority against PCB in a multicenter randomized trial.
- Primary endpoints included primary patency and a composite clinical endpoint at 12 months.
- Results showed SCB achieved noninferior clinical outcomes compared to PCB, though primary patency noninferiority was not statistically robust.
- SCB may be a valuable alternative to PCB for femoropopliteal artery disease.
- Study funded by an unrestricted grant from Concept Medical Inc, with no role in study design or analysis.